PureTech Health (PRTC) 2016年年度报告「LSE」.pdf

1、Giving Life to SciencePureTech Health plc Annual report and accounts 2016PureTech Health plc Annual report and accounts 2016 1OverviewIFCB PureTech Health plc Annual report and accounts 2016Highlights of the Year 2016Consolidated cash and short term investments:$281.5m2015:$313.7m 2014:$62.7mPureTec

2、h cash and short term investments:$192.1m2015:$255.5m 2014:$53.2mValue of growth stage programmes:$380.1m2015:$291.7m 2014:$222.4mNumber of patents and patent applications:2882015:209 2014:111Number of project stage programmes advanced:32015:3 2014:2Number of partnerships entered:62015:4 2014:2Numbe

3、r of theme-based technologies sourced:9182015:776 2014:521In 2016,the Groups programmes attracted in excess of$98 million in funding,including$50.0 million by Vedanta Biosciences and over$42.4 million by Akili with$29.3 million provided from leading strategic and financial institutions such as Amgen

4、 Ventures,Merck Ventures BV,Amsterdam,The Netherlands,a subsidiary of Merck KGaA,Darmstadt,Germany(known as M Ventures in the United States and Canada),Rock Springs Capital,Seventure,JAZZ Venture Partners,and Canepa Advanced Healthcare Fund.Key clinical and technical advancements made in 2016 are li

5、sted below:Initiated a pivotal study of Akilis Project:EVOTM in paediatric attention deficit hyperactivity disorder(ADHD)Initiated the US portion of a pivotal study of Gelesis100 in people who are overweight or have obesity Announced positive results from a tolerability proof-of-concept clinical stu

6、dy with Karunas lead programme for the treatment of schizophrenia and Alzheimers disease psychosis and cognition impairment Presented positive top line safety data and positive satiety data from a second Gelesis candidate in obesity(Gelesis 200)Presented positive top line data from the Akili Alzheim